Virologic failure among children taking lopinavir/ritonavir-containing first-line antiretroviral therapy in South Africa - Wikidata - wikimedia - TriplyDB

Virologic failure among children taking lopinavir/ritonavir-containing first-line antiretroviral therapy in South Africa

Virologic failure among children taking lopinavir/ritonavir-containing first-line antiretroviral therapy in South Africa

http://www.wikidata.org/entity/Q35156697

about

Sequencing paediatric antiretroviral therapy in the context of a public health approach Tuberculosis: opportunities and challenges for the 90-90-90 targets in HIV-infected children Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014.Getting to 90-90-90 in paediatric HIV: What is needed?Tuberculosis and pneumonia in HIV-infected children: an overview Virological response and resistances over 12 months among HIV-infected children less than two years receiving first-line lopinavir/ritonavir-based antiretroviral therapy in Cote d'Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort.Antiretroviral Treatment and Resistance Patterns in HIV-Infected Children.Multicentre analysis of second-line antiretroviral treatment in HIV-infected children: adolescents at high risk of failure.Targeting 90-90-90--don't leave children and adolescents behind.Impact of Human Immunodeficiency Virus Drug Resistance on Treatment of Human Immunodeficiency Virus Infection in Children in Low- and Middle-Income Countries.

P2860

Q26774261-140C800E-71BE-4E2A-BAA6-EA65630A2CBF Q26774267-0892B1A8-D66A-407C-B29B-6B0A70C7E8AE Q30359339-6ABB11CD-81FB-48C0-988D-5F2A81175A69 Q30385352-548961F2-7AF3-46BE-B2F8-7916395F0AFB Q33801297-90D75C1C-9E58-4B39-9229-7BA61FCC8CD9 Q40223405-F57F6092-C811-4467-9586-436DD8B12887 Q41026791-AB33055B-1A9A-42D6-A20B-3077BFF069E1 Q41929466-E50E006F-C1F1-4EC6-A760-9D52B546E6F3 Q43142354-7338B7F1-5D18-41C6-81D9-23A289EFC201 Q45326130-B6BD852F-D539-4BCC-93B3-B94F4241CA37

P2860

Virologic failure among children taking lopinavir/ritonavir-containing first-line antiretroviral therapy in South Africa

http://www.wikidata.org/entity/Q35156697

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Virologic failure among childr ...... oviral therapy in South Africa

@ast

Virologic failure among childr ...... oviral therapy in South Africa

@en

type

label

Virologic failure among childr ...... oviral therapy in South Africa

@ast

Virologic failure among childr ...... oviral therapy in South Africa

@en

prefLabel

Virologic failure among childr ...... oviral therapy in South Africa

@ast

Virologic failure among childr ...... oviral therapy in South Africa

@en

P1433

Q35156697-17622390-F83B-4F13-BACB-98EE8CF16F06

P1476

Q35156697-93862337-4302-4DA5-BFB0-0225D1CADB92

P2093

Q35156697-123BE0D9-8374-43F6-8778-3A1E4500D502

Q35156697-22514A0C-D8D0-471B-90A0-BA342EE4756C

Q35156697-4102A3BC-C3E0-4491-94E2-FAA7AE6A7B4B

Q35156697-8EE25BC1-6ECE-4F00-A6B7-F7D2E2675587

Q35156697-A7BC0D5B-5162-49C1-8DFB-1C6024C509EE

Q35156697-AE95837C-2679-4669-9386-A3341C02A5BD

P2860

Q35156697-138354C0-2F66-43E2-8BA3-08251083738C

Q35156697-2FAE435D-6C16-45E5-9B34-FC2CED95FAB5

Q35156697-35C9368E-E05A-4539-BE35-22C66E244FC4

Q35156697-3B650EBA-89DD-4D94-BFFE-7D801D4FDFA0

Q35156697-3BEDADA4-1610-4593-93EF-B0B3C064E9A9

Q35156697-3FE16505-9CFA-4BA5-8CD6-83AFA14CA3DC

Q35156697-4FE87555-1A72-48AC-9268-8F136C1B64FF

Q35156697-5CCF59B0-FC60-44DA-96FE-D7988923DC87

Q35156697-63884994-26DD-4393-BFD9-8F2EAB7CF915

Q35156697-63BCA04F-612B-4219-A38E-4EA5BD885A5A

P304

Q35156697-24809ED4-7DE9-443C-82B3-F4AFE81CBA2E

P31

Q35156697-D9535964-3022-4BB7-B71A-B08D7C3D950E

P356

Q35156697-1413FC80-2C8F-4E9C-91BB-1EE56BFEE398

P433

Q35156697-A72DF662-379B-4742-84D8-BEBED1504350

P478

Q35156697-2C3601FB-9373-4DEB-94DC-2BC99F010F89

P50

Q35156697-48937063-A12D-4D9C-9002-1BFCF05F9200

P577

Q35156697-13380B79-758F-441C-B00B-69862B613C87

P698

Q35156697-98E830FA-ACD9-431E-99AF-7B6F1EB40962

P921

Q35156697-0714E765-5CBF-45F0-B803-238C1DBA99EB

Q35156697-6474943C-BF1D-41D3-B346-0C90D29F4926

Q35156697-C152519C-B394-4212-A3B4-051B1398FBBC

P932

Q35156697-9F4B01CF-36D7-47B6-A871-5051EA7FA7E7

P356

INF.0000000000000544

P1433

Pediatric Infectious Disease Journal

P1476

Virologic failure among childr ...... oviral therapy in South Africa

@en

P2093

Francoise Pinillos

http://www.w3.org/2001/XMLSchema#string

Harry Moultrie

http://www.w3.org/2001/XMLSchema#string

Jessica Y Wong

http://www.w3.org/2001/XMLSchema#string

Lee Fairlie

http://www.w3.org/2001/XMLSchema#string

Shobna Sawry

http://www.w3.org/2001/XMLSchema#string

Tammy Meyers

http://www.w3.org/2001/XMLSchema#string

P2860

Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach

Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.

Virologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: a South African multi-cohort analysis

Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment.

Outcomes of the South African National Antiretroviral Treatment Programme for children: the IeDEA Southern Africa collaboration.

Pediatric response to second-line antiretroviral therapy in South Africa

Antiretroviral treatment for children with peripartum nevirapine exposure.

First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.

Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.

P304

175-179

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/INF.0000000000000544

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25741970

http://www.w3.org/2001/XMLSchema#string

P921

Aafrikaa Kibbaa

antiretroviral drug

P932

4352713

http://www.w3.org/2001/XMLSchema#string